References

Benjamini, Yoav, and Yosef Hochberg. 1995. “Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing.” Journal of the Royal Statistical Society: Series B (Methodological) 57 (1): 289–300. https://doi.org/10.1111/j.2517-6161.1995.tb02031.x.

Breslow, Norman E, Thomas Lumley, Christie M Ballantyne, Lloyd E Chambless, and Michal Kulich. 2009. “Using the Whole Cohort in the Analysis of Case-Cohort Data.” American Journal of Epidemiology 169 (11): 1398–405.

Breslow, Norman, Brad McNeney, and Jon A Wellner. 2003. “Large Sample Theory for Semiparametric Regression Models with Two-Phase, Outcome Dependent Sampling.” The Annals of Statistics 31 (4): 1110–39.

Dı́az, Iván, and Mark J van der Laan. 2012. “Population Intervention Causal Effects Based on Stochastic Interventions.” Biometrics 68 (2): 541–49.

Dı́az, Iván, Nicholas Williams, Katherine L Hoffman, and Edward J Schenck. 2023. “Nonparametric Causal Effects Based on Longitudinal Modified Treatment Policies.” Journal of the American Statistical Association 118 (542): 846–57. https://doi.org/10.1080/01621459.2021.1955691.

Gilbert, Peter B, Youyi Fong, David Benkeser, et al. 2021. CoVPN COVID-19 Vaccine Efficacy Trial Immune Correlates Statistical Analysis Plan. https://doi.org/10.6084/m9.figshare.13198595.

Gilbert, Peter B, Youyi Fong, Nima S Hejazi, et al. 2024. “Four Statistical Frameworks for Assessing an Immune Correlate of Protection (Surrogate Endpoint) from a Randomized, Controlled, Vaccine Efficacy Trial.” Vaccine 42 (9): 2181–90. https://doi.org/10.1016/j.vaccine.2024.02.071.

Gilbert, Peter B, Youyi Fong, Avi Kenny, and Marco Carone. 2023. “A Controlled Effects Approach to Assessing Immune Correlates of Protection.” Biostatistics 24 (4): 850–65. https://doi.org/10.1093/biostatistics/kxac024.

Gilbert, Peter B, David C Montefiori, Adrian B McDermott, et al. 2021. “Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial.” Science 375 (6576): 43–50. https://doi.org/10.1126/science.abm3425.

Gruber, Susan, and Mark J van der Laan. 2010. “A Targeted Maximum Likelihood Estimator of a Causal Effect on a Bounded Continuous Outcome.” The International Journal of Biostatistics 6 (1). https://doi.org/10.2202/1557-4679.1260.

Haneuse, Sebastian, and Andrea Rotnitzky. 2013. “Estimation of the Effect of Interventions That Modify the Received Treatment.” Statistics in Medicine 32 (30): 5260–77.

Hejazi, Nima S, and David C Benkeser. 2020. “txshift: Efficient Estimation of the Causal Effects of Stochastic Interventions in R.” Journal of Open Source Software 5 (54): 2447. https://doi.org/10.21105/joss.02447.

Hejazi, Nima S, Philippe Boileau, Mark J van der Laan, and Alan E Hubbard. 2023. “A Generalization of Moderated Statistics to Data Adaptive Semiparametric Estimation in High-Dimensional Biology.” Statistical Methods in Medical Research 32 (3): 539–54. https://doi.org/10.1177/09622802221146313.

Hejazi, Nima S, Xiaoying Shen, Lindsay N Carpp, et al. 2023. “Stochastic Interventional Approach to Assessing Immune Correlates of Protection: Application to the COVE mRNA-1273 Vaccine Trial.” International Journal of Infectious Diseases 137: 28–39. https://doi.org/10.1016/j.ijid.2023.09.012.

Hejazi, Nima S, Mark J van der Laan, Holly E Janes, Peter B Gilbert, and David C Benkeser. 2021. “Efficient Nonparametric Inference on the Effects of Stochastic Interventions Under Two-Phase Sampling, with Applications to Vaccine Efficacy Trials.” Biometrics 77 (4): 1241–53. https://doi.org/10.1111/biom.13375.

Huang, Ying, Nima S Hejazi, Bryan Blette, et al. 2023. “Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection Against Symptomatic COVID-19 in the COVE mRNA-1273 Trial.” Viruses 15 (10): 2029. https://doi.org/10.3390/v15102029.

Joehanes, Roby, Allan C. Just, Riccardo E. Marioni, et al. 2016. “Epigenetic Signatures of Cigarette Smoking.” Circulation: Cardiovascular Genetics 9 (5): 436–47. https://doi.org/10.1161/CIRCGENETICS.116.001506.

Plotkin, Stanley A, and Peter B Gilbert. 2012. “Nomenclature for Immune Correlates of Protection After Vaccination.” Clinical Infectious Diseases 54 (11): 1615–17.

Prentice, Ross L. 1986. “A Case-Cohort Design for Epidemiologic Cohort Studies and Disease Prevention Trials.” Biometrika 73 (1): 1–11.

Prentice, Ross L. 1989. “Surrogate Endpoints in Clinical Trials: Definition and Operational Criteria.” Statistics in Medicine 8 (4): 431–40.

Rose, Sherri, and Mark J van der Laan. 2011. “A Targeted Maximum Likelihood Estimator for Two-Stage Designs.” The International Journal of Biostatistics 7 (1): 1–21.

Smyth, Gordon K. 2004. “Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments.” Statistical Applications in Genetics and Molecular Biology 3 (1): 1–25. https://doi.org/10.2202/1544-6115.1027.

Su, Dan, Xuting Wang, Michelle R Campbell, et al. 2016. “Distinct Epigenetic Effects of Tobacco Smoking in Whole Blood and Among Leukocyte Subtypes.” PLoS ONE 11 (12): e0166486. https://doi.org/10.1371/journal.pone.0166486.

Tuglus, Catherine, and Mark J van der Laan. 2009. “Modified FDR Controlling Procedure for Multi-Stage Analyses.” Statistical Applications in Genetics and Molecular Biology 8 (1). https://doi.org/10.2202/1544-6115.1397.

White, J Emily. 1982. “A Two Stage Design for the Study of the Relationship Between a Rare Exposure and a Rare Disease.” American Journal of Epidemiology 115 (1): 119–28.